Abstract: Objective: To systematically review the effectiveness and safety of safflower yellow for acute cerebral infarction (ACI), And analyze its drug cost-effectiveness. Methods: Relevant studies of safflower yellow for ACI were collected from databases including Cochrane, MEDLINE, EMbase, CNKI, VIP and WanFang Data from January, 2000 to March, 2014, and the relevant journals and conference proceedings were also manually retrieved. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data and assessed the quality of the included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results: A total of six literatures of according with the selected standards were included in this study.The results showed that compared with control group，the pooled OR value of clinical effectiveness for safflower yellow injection was 3.05( 95% CI:1.96～4.76), and the pooled WMD value of effectiveness for improving neurological function impairment score was -4.05( 95% CI 为-5.65～-2.44), but it lacks economic advantage. Conclusion: Current evidence showed that, safflower yellow plus routine biomedical treatment is effective in the treatment of acute cerebral infarction (ACI), which is superior to routine biomedical treatment alone. Due to the limited quantity and quality of the included studies, more high quality, double blind, randomized controlled trials are needed to verify the above conclusion.